COSMO BIO COMPANY,LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 975 JPY | -0.71% |
|
-2.01% | -0.81% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,211 | 6,213 | 7,268 | 6,730 | 5,878 | 5,736 |
| Enterprise Value (EV) 1 | 2,963 | 3,717 | 4,029 | 3,195 | 2,862 | 2,731 |
| P/E ratio | 20 x | 26.2 x | 10.8 x | 9.16 x | 11.4 x | 13 x |
| Yield | 1.59% | 1.34% | 2.77% | 3.1% | 3.56% | 3.05% |
| Capitalization / Revenue | 0.72 x | 0.82 x | 0.9 x | 0.73 x | 0.62 x | 0.61 x |
| EV / Revenue | 0.41 x | 0.49 x | 0.5 x | 0.35 x | 0.3 x | 0.29 x |
| EV / EBITDA | 5.9 x | 6.06 x | 4.34 x | 2.63 x | 2.99 x | 4.08 x |
| EV / FCF | 4.58 x | 11.6 x | 5.49 x | 11 x | 19.4 x | 5.67 x |
| FCF Yield | 21.8% | 8.63% | 18.2% | 9.08% | 5.16% | 17.6% |
| Price to Book | 0.79 x | 0.91 x | 0.99 x | 0.86 x | 0.73 x | 0.68 x |
| Nbr of stocks (in thousands) | 5,928 | 5,928 | 5,928 | 5,792 | 5,814 | 5,835 |
| Reference price 2 | 879.0 | 1,048 | 1,226 | 1,162 | 1,011 | 983.0 |
| Announcement Date | 3/27/19 | 3/25/20 | 3/24/21 | 3/24/22 | 3/24/23 | 3/27/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 7,261 | 7,590 | 8,092 | 9,231 | 9,553 | 9,340 |
| EBITDA 1 | 502 | 613 | 928 | 1,216 | 958 | 669 |
| EBIT 1 | 324 | 406 | 753 | 1,050 | 817 | 521 |
| Operating Margin | 4.46% | 5.35% | 9.31% | 11.37% | 8.55% | 5.58% |
| Earnings before Tax (EBT) 1 | 402 | 387 | 1,008 | 1,098 | 790 | 652 |
| Net income 1 | 260 | 237 | 674 | 737 | 517 | 442 |
| Net margin | 3.58% | 3.12% | 8.33% | 7.98% | 5.41% | 4.73% |
| EPS 2 | 43.86 | 39.98 | 113.7 | 126.9 | 89.06 | 75.83 |
| Free Cash Flow 1 | 646.5 | 320.8 | 733.6 | 290.2 | 147.6 | 481.6 |
| FCF margin | 8.9% | 4.23% | 9.07% | 3.14% | 1.55% | 5.16% |
| FCF Conversion (EBITDA) | 128.78% | 52.32% | 79.05% | 23.87% | 15.41% | 71.99% |
| FCF Conversion (Net income) | 248.65% | 135.34% | 108.85% | 39.38% | 28.55% | 108.96% |
| Dividend per Share 2 | 14.00 | 14.00 | 34.00 | 36.00 | 36.00 | 30.00 |
| Announcement Date | 3/27/19 | 3/25/20 | 3/24/21 | 3/24/22 | 3/24/23 | 3/27/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 S1 | 2022 Q1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2023 S2 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,946 | 4,835 | 3,047 | 5,111 | 2,016 | 2,828 | 4,827 | 2,050 | - | 2,943 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 431 | 716 | 578 | 626 | 77 | 400 | 458 | -11 | - | 305 |
| Operating Margin | 10.92% | 14.81% | 18.97% | 12.25% | 3.82% | 14.14% | 9.49% | -0.54% | - | 10.36% |
| Earnings before Tax (EBT) 1 | 673 | 752 | 565 | 620 | 70 | 416 | 552 | 2 | - | 353 |
| Net income 1 | 450 | 490 | 366 | 407 | 47 | 264 | 361 | 5 | - | 230 |
| Net margin | 11.4% | 10.13% | 12.01% | 7.96% | 2.33% | 9.34% | 7.48% | 0.24% | - | 7.82% |
| EPS 2 | 76.00 | 84.19 | 63.23 | 70.28 | 7.930 | 45.46 | 62.04 | 0.8000 | - | 39.56 |
| Dividend per Share | 8.000 | 12.00 | - | 16.00 | - | - | 14.00 | - | 16.00 | - |
| Announcement Date | 8/5/20 | 8/5/21 | 5/10/22 | 8/4/22 | 11/7/22 | 5/10/23 | 8/4/23 | 11/7/23 | 2/14/24 | 5/9/24 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 2,248 | 2,496 | 3,239 | 3,535 | 3,016 | 3,005 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 647 | 321 | 734 | 290 | 148 | 482 |
| ROE (net income / shareholders' equity) | 3.99% | 3.41% | 9.24% | 9.49% | 6.52% | 5.23% |
| ROA (Net income/ Total Assets) | 2.44% | 2.92% | 5.08% | 6.66% | 5.01% | 3.07% |
| Assets 1 | 10,675 | 8,122 | 13,269 | 11,069 | 10,320 | 14,378 |
| Book Value Per Share 2 | 1,110 | 1,154 | 1,241 | 1,344 | 1,385 | 1,447 |
| Cash Flow per Share 2 | 349.0 | 408.0 | 533.0 | 562.0 | 522.0 | 484.0 |
| Capex 1 | 51 | 141 | 36 | 31 | 55 | 67 |
| Capex / Sales | 0.7% | 1.86% | 0.44% | 0.34% | 0.58% | 0.72% |
| Announcement Date | 3/27/19 | 3/25/20 | 3/24/21 | 3/24/22 | 3/24/23 | 3/27/24 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -0.81% | 36.87M | |
| -28.10% | 1.35B | |
| -19.52% | 56.65M |
- Stock Market
- Equities
- 3386 Stock
- Financials Cosmo Bio Company,Limited